Sedative, Hypnotic, or Anxiolytic Use Disorder
This category includes benzodiazepines, barbiturates, and non-benzodiazepine hypnotics (“Z-drugs”). Misuse is characterized by a high risk of physiological dependence and severe, potentially life-threatening withdrawal.
Key Clinical Considerations
| Feature | Description |
|---|---|
| Intoxication | Slurred speech, incoordination, unsteady gait, nystagmus, impaired attention, and stupor or coma. |
| Withdrawal | Autonomic hyperactivity, hand tremor, insomnia, nausea/vomiting, transient hallucinations, anxiety, and seizures. |
High-Yield Clinical Notes:
- Withdrawal Management: Abrupt cessation can be fatal. Use a tapering protocol, often by switching the patient to a long-acting benzodiazepine (e.g., Diazepam or Chlordiazepoxide) before gradually reducing the dose.
- Overdose Risk: Synergistic effects with other CNS depressants (especially alcohol or opioids) significantly increase the risk of fatal respiratory depression.
- Flumazenil: A $GABA_A$ receptor antagonist used to reverse benzodiazepine overdose. Caution: Must be used carefully as it can precipitate acute, severe withdrawal seizures in long-term users.
- Elderly Population: Increased sensitivity to these agents; associated with cognitive impairment, falls, and hip fractures. Avoid if possible.